Rethinking treatment for nervous system disorders
Empowering patients to live on their own terms

Who We Are

At its core, Eliem is motivated by the promise of helping people live happier, more fulfilling lives. The Eliem team channels its experience, energy and passion for improving patients’ quality of life by developing life-changing novel therapies for neuronal excitability disorders based on clinically validated mechanisms of action.

Our Approach: Optimizing Treatments for Neuronal Excitability Disorders

Tens of millions of people suffer from central and peripheral nervous system disorders, where an imbalance between excitation and inhibition has disrupted the homeostasis in affected neuronal networks. These disorders include a range of common conditions such as chronic pain, depression, epilepsy and anxiety. Currently available treatments for these conditions often fail to provide adequate control or relief, and they are often poorly tolerated, leaving people unable to live life on their own terms.

Developing improved treatments for patients requires a pragmatic and diligent approach. Equal parts rigorous and agile, the experienced Eliem team strives to make treatments that are more effective, safer and better tolerated than currently available treatments. Leveraging clinically validated mechanisms of action, we are moving steadily and efficiently to develop novel therapeutics for neuronal excitability disorders that deliver enhanced outcomes for patients.

Our Pipeline

Our two lead drug candidates have clinically validated mechanisms of action for neurological diseases and have demonstrated encouraging clinical and preclinical results. We are developing ETX-810 for chronic pain and ETX-155 for major depressive disorder, perimenopausal depression and focal onset seizures. These compounds are designed to dramatically improve on the limitations of existing therapies with the potential to be best-in-class for these conditions with high unmet clinical needs.

Learn More

Our Experienced Team

Eliem is founded and led by a team of seasoned industry executives who collectively bring decades of clinical development and biopharmaceutical commercialization experience to the company. The team not only shares an unparalleled determination and passion to help patients, but they also have a history of working together to successfully build companies and bring novel and effective therapies to market. Eliem is also advised by a Board with considerable neurology research and development experience and a strong track record of building successful companies.

The team’s combined expertise in neurological research, clinical development, commercialization and company building are critical for delivering on the promise of bringing innovative therapies to market to provide relief and hope for the millions of patients affected by neurological conditions.
Leadership Team Board of Directors
Leadership Team
Board of Directors
Bob Azelby
President and Chief Executive Officer
Bob Azelby
President and Chief Executive Officer
Bob most recently served as the President and CEO of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.3 billion in 2019. Previously, he was Juno Therapeutics’ Executive Vice President and Chief Commercial Officer, participating in the management of all aspects of Juno’s operations and accountable for leading and developing Juno’s commercial capabilities. Juno was acquired by Celgene for $9 billion in 2018. Prior to Juno, Bob was the Vice President and General Manager of Amgen’s US Oncology Business Unit, responsible for $6.5 billion annual net revenue. Over his 15-year career with Amgen, Bob held numerous sales and marketing positions, including Vice President of US Oncology Sales, Vice President of North American Commercial Operations, General Manager for Amgen Netherlands and Senior Marketing Director. He is currently a member of the Clovis Oncology Board of Directors and was formerly on the Immunomedics and Cascadian Therapeutics Board of Directors. Bob received his undergraduate degrees in economics and religious studies from the University of Virginia and his master of business administration from Harvard University.
Valerie Morisset, Ph.D.
Executive Vice President, R&D and Chief Scientific Officer
Valerie Morisset, Ph.D.
Executive Vice President, R&D and Chief Scientific Officer
Valerie is Co-Founder and Chief Scientific Officer of Eliem Therapeutics. Valerie has more than 20 years’ experience in the pharmaceutical industry, with positions of increasing responsibility at Novartis, GSK, Convergence and Biogen. Prior to joining Eliem, Valerie was a founding venture partner at Bridge Valley Ventures. She co-founded Convergence Pharmaceuticals, where she established and led the Biology and Translational Medicine team, and she was instrumental in the sale of Convergence to Biogen for $675M in 2015. Valerie subsequently joined Biogen in a senior leadership role. She has worked extensively in the field of drug development for pain and across a number of other therapeutic areas including neurology, psychiatry, gastrointestinal disorders and sensory biology. Valerie trained as an electrophysiologist and completed her doctorate at the University of Bordeaux.
Erin Lavelle
Executive Vice President, Chief Operating Officer & Chief Financial Officer
Erin Lavelle
Executive Vice President, Chief Operating Officer & Chief Financial Officer
Erin has more than 20 years of cross-functional experience leading strategic and operational initiatives in the biopharmaceutical industry. Erin was Chief Operating Officer of Alder BioPharmaceuticals, leading the company’s readiness for launch of its first therapy, including enterprise planning around supply chain, compliance and information technology. She led the company’s $2.3 billion sale to H. Lundbeck in 2019. Prior to Alder, Erin worked at Amgen for 15 years in a variety of roles in the corporate development, finance and commercial organizations. Her most recent role was General Manager of Amgen Taiwan, where she managed a portfolio of six commercialized products. Erin worked in Hong Kong as an Executive Director for the Japan Asia-Pacific region during its initial build. She began her career as an investment banker focused on biotech M&A and financing in the healthcare group at Merrill Lynch & Co. Erin is currently a member of the Neoleukin Therapeutics Board of Directors and serves as President of the Seattle chapter of the Healthcare Businesswomen’s Association (HBA). She holds a bachelor of arts in economics from Yale University.
James Bucher, J.D.
Executive Vice President & General Counsel
James Bucher, J.D.
Executive Vice President & General Counsel
Jim served as Executive Vice President and General Counsel of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.3 billion in 2019. Jim was a standing member of Alder’s Executive Team, participating in the management of all aspects of Alder’s strategy and operations, with direct responsibility for the company’s legal affairs, intellectual property, risk management, and compliance. Prior to joining Alder, Jim was Vice President of Corporate Legal Affairs and Secretary as well as the Corporate Compliance Officer of Exelixis, a NASDAQ-listed biopharmaceutical company. He was a partner at the international law firm Shearman & Sterling LLP, serving with the firm for 16 years. Jim has significant experience with capital raising, including execution of six equity and convertible debt financings generating over $900 million in capital for Alder and eight equity and debt financings generating over $1 billion in capital for Exelixis. Jim holds a juris doctorate with distinction from Emory University School of Law and a bachelor of arts in biology from Colgate University.
Amy Chappell, M.D.
Chief Medical Officer
Amy Chappell, M.D.
Chief Medical Officer
Amy has 32 years of CNS clinical drug development experience first at Eli Lilly and Company, followed by extensive consulting for small and large pharmaceutical companies. Her most recent position was Vice President, Neuroscience, at PPD, a contract research organization. Amy has deep expertise in translational neuroscience and in all phases of clinical drug development across a wide range of neurological indications including epilepsy, ALS, Parkinson’s, Alzheimer’s, multiple pain types, migraine and multiple sclerosis. She has interacted with multiple regulatory agencies and was the medical lead on the development and NDA submission of duloxetine for fibromyalgia that resulted in an FDA approval. She is the author of many peer-reviewed scientific publications. Amy is certified by the American Board of Neurology and Psychiatry (neurology with special competency in child), the American Academy of Pediatrics (specialty certification) and the American Board of Lifestyle Medicine. She has 40 years of clinical practice experience in child and adult neurology and holds active Florida and Indiana medical licenses. She received her bachelor of science from Antioch College and medical degree from the Indiana University School of Medicine. She completed her post-doctoral training at the Johns Hopkins Hospital (pediatric residency and epilepsy fellowship) and the Indiana University Medical Center (neurology residency).
Jo Palmer-Phillips, Ph.D.
Chief Development Officer
Jo Palmer-Phillips, Ph.D.
Chief Development Officer
Jo is a neuropsychologist with over 18 years’ experience working in clinical development in the pharmaceutical industry with a focus on pain and migraine. She has held positions in both clinical operations and clinical strategy including leading multidisciplinary clinical teams at Roche, GSK, Convergence Pharmaceuticals and Biogen. Jo was a founding member of Convergence Pharmaceuticals Ltd and a member of the leadership team. As the Head of Clinical Operations at Convergence, she was responsible for designing and managing the full-service outsourcing of phase 1 and 2 clinical studies in pain. She was also responsible for establishing and maintaining the Quality System.
Andrew Levin, M.D., Ph.D.
(Chairman)
Andrew Levin, M.D., Ph.D.
(Chairman)
Andrew is a Co-Founder of Eliem Therapeutics and Chairman of the Board of Directors. In addition to co-founding Eliem, Andrew spearheads drug discovery efforts at RA Capital Management, L.P. that have led to the formation of several companies and serves as a Managing Director on the Investment Team. Previously, Andrew was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. He holds a bachelor of science in mechanical engineering from Princeton University, a doctorate in biomedical engineering from the Massachusetts Institute of Technology and a medical degree from Harvard Medical School.
Bob Azelby
Bob Azelby
Bob most recently served as the President and CEO of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.3 billion in 2019. Previously, he was Juno Therapeutics’ Executive Vice President and Chief Commercial Officer, participating in the management of all aspects of Juno’s operations and accountable for leading and developing Juno’s commercial capabilities. Juno was acquired by Celgene for $9 billion in 2018. Prior to Juno, Bob was the Vice President and General Manager of Amgen’s US Oncology Business Unit, responsible for $6.5 billion in annual net revenue. Over his 15-year career with Amgen, Bob held numerous sales and marketing positions including Vice President of US Oncology Sales, Vice President of North American Commercial Operations, General Manager for Amgen Netherlands, Senior Marketing Director, etc. He is currently a member of the Clovis Oncology Board of Directors and was formerly on the Immunomedics and Cascadian Therapeutics’ Board of Directors. Bob received his undergraduate degrees in economics and religious studies from the University of Virginia and his master of business administration from Harvard University.
Judith Dunn, Ph.D.
Judith Dunn, Ph.D.
Judy is the President and Head of R&D at Fulcrum Therapeutics.  Prior to this role, Judy was an Entrepreneur-in-Residence at Atlas Venture, where she focused on new company creation. Previously, Judy served as Vice President and Global Head of Clinical Development at Roche in Basel, Switzerland, and Head of the Roche Innovation Center in NYC. She has held leadership positions in both the research and commercial neuroscience divisions of Pfizer and in clinical psychiatry at Sepracor. Judy is currently an independent board director at Evolution Research Group and a member of the NYC Mayor’s Advisory Council on Life Sciences. She has also served as a scientific advisor to the Tri-Institutional Therapeutics Discovery Institute and as a board member of the Partnership for NY Fund.
Leone Patterson
Leone Patterson
Leone is chief financial and business officer of Tenaya Therapeutics, where she leads corporate finance, investor relations, corporate communications, strategy and business development, as well as other operational functions. She has over 20 years of experience in the biotechnology industry. Prior to Tenaya, Leone served as President and Chief Financial Officer of Adverum Biotechnologies, and previously held the positions of CEO and Director. Prior to Adverum, she was Chief Financial Officer at both Diadexus and Transcept Pharmaceuticals.  She also held senior finance positions at Exelixis, Novartis, and Chiron. Leone began her career at KPMG working in the firm’s audit practice. She earned a bachelor of science in business administration and accounting from Chapman University and an executive master of business administration from St. Mary’s College. She is also a Certified Public Accountant (inactive status). She currently serves on the board of directors for Nkarta, Inc.
Liam Ratcliffe, M.D., Ph.D.
Liam Ratcliffe, M.D., Ph.D.
Liam is the head of Access Biotechnology, the strategic investment arm specializing in therapeutic platforms and products at Access Industries. Prior to his work at Access Industries, he was Managing Director at New Leaf Venture Partners, where he concentrated on biopharmaceutical investing. Prior to joining New Leaf in 2008, Liam served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Midwest region (based in Ann Arbor, Mich.) and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. He received his medical degree and doctorate in immunology from the University of Cape Town and his master of business administration from the University of Michigan. He completed his internal medicine training and fellowship in immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.
Adam Rosenberg
Adam Rosenberg
Adam is a Venture Partner at RA Capital Management. Adam currently serves on other private company boards and is Chair of Ambagon Therapeutics. Adam was most recently President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Adam was also an advisor and investor in “A Late Quartet”, an entrepreneurial feature film centered on a cellist diagnosed with Parkinson’s disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College.
Simon Tate
Simon Tate
Simon is a Managing Director at Intermediate Capital Group (ICG) and has 30 years of experience in R&D. He has spent most of his career working in the fields of Pain and Neuroscience. He was one of the founders of Convergence Pharmaceuticals, and as Chief Scientific Officer and head of R&D, he led Convergence to its successful acquisition by Biogen for $675M in 2015. Following this acquisition, Simon joined Biogen, where he assumed the role of Vice President and Head of the Pain Therapeutic Area. Prior to Convergence, Simon was Vice President and Head of Pain, Epilepsy, and Migraine drug discovery and early development in GSK, where he held senior roles in Neurology, Psychiatry, and Discovery Sciences during his 20-year career. Originally trained as a Biochemist, Simon graduated from the University of Dundee, where he had the privilege to work with Sir Philip Cohen, who was, at the time, the world’s third most cited professor.

News

Eliem Therapeutics Reports Second Quarter Financial Results

On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash runway through late 2023 SEATTLE and CAMBRIDGE,

Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central
Load More
09/13/2021
Eliem Therapeutics Reports Second Quarter Financial Results
On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash runway through late 2023 SEATTLE and CAMBRIDGE,
08/13/2021
Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central
08/10/2021
Eliem Therapeutics Announces Pricing of Initial Public Offering
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the
05/24/2021
Eliem Therapeutics Announces $60 Million Series B Financing
Advances two clinical programs through topline data across four indications Progresses two preclinical programs to potential lead candidate selection Brings total funding since inception to $140 million SEATTLE and CAMBRIDGE, UK –(BUSINESS WIRE) – May 24, 2021 – Eliem Therapeutics, Inc., a
03/25/2021
Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders
SEATTLE and CAMBRIDGE, England, March 25, 2021 /PRNewswire/ — Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today with $80 million in financing since its inception in 2019.

Careers

We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.

We’d love to connect.

Open Positions
Senior Manager – Technical Accounting and SEC Reporting
Senior Manager – Technical Accounting and SEC Reporting

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We are looking for a Senior Manager – Technical Accounting and SEC Reporting to join our growing global Accounting team. This is a crucial role that will assist in overseeing financial reporting in our transition to a public company. This role will report to the VP of Accounting and work with key internal and external stakeholders to deliver timely internal and external reporting in accordance with GAAP.

Responsibilities:

  • Manage SEC filings and supporting documents, including Form 10-K, 10-Q, proxy statements, and other required form filings
  • Independently research and analyze accounting issues and disclosure requirements in accordance with US GAAP and SEC reporting requirements
  • Preparing cash flows, stockholders’ rollforward, EPS calculation, stock-based compensation, and accounting for non-routine transactions
  • Complete disclosure checklists to ensure all disclosure requirements are met; research disclosure requirements and keep abreast of new pronouncements impacting disclosures; establish a repository of internal practices and peer company disclosures
  • Monitor proposed and enacted accounting pronouncements that affect the Company and make recommendations on implementing changes/compliance
  • Collaborate with finance, investor relations and legal on external stakeholder financial communications
  • Review XBRL tagging in connection with Form 10-K and 10-Q filings
  • Ensure compliance with Sarbanes-Oxley (SOX) controls as it pertains to financial reporting and
    equity processes
  • Assist with the implementation of accounting and other systems for better financial and operational reporting and an improved control environment
  • Assist in various ongoing and ad-hoc projects or initiatives as needed

Experience:

  • Bachelor’s degree in Accounting/Finance and CPA required
  • Strong, current understanding of US GAAP and SEC reporting rules and regulations
  • 6+ years of experience in accounting; including Big 4 public accounting experience and
    experience with financial reporting in a public company
  • Strong project management skills and the ability to manage a process and team to multi-task,
    work under pressure, and meet deadlines in a fast-paced work environment
  • Active Disclosure and XBRL experience preferred
  • Strong organizational, verbal, and written communication skills are a must
  • Accounting research and problem-solving skills required
  • Ability to build strong relationships with internal and external business partners
  • Ability to operate independently and as part of a larger functional team
  • Proficient with Microsoft Office – Word, Excel, and PowerPoint
  • Experience with NetSuite is a plus

Benefits

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Qualified candidates are encouraged to forward their resume to CareersUS@eliemtx.com

Senior Corporate Counsel
Senior Corporate Counsel

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

The Senior Corporate Counsel is a newly created position at Eliem and will play a key role in the company’s legal department. Reporting directly to Eliem’s Executive Vice President and General Counsel, they will enjoy a varied role advising the company’s teams in the United States and United Kingdom. The Senior Corporate Counsel will work on a broad range of contracts, general corporate, compliance, governance, securities, human resources, benefits, and business development matters, and provide effective, business-focused legal advice and counsel to stakeholders across the organization. The level of counseling requires a deep understanding of life sciences businesses and related legal issues, as well as outstanding drafting and negotiation skills. The Senior Corporate Counsel may also provide support on various intellectual property matters as needed.

Responsibilities:

  • Lead the drafting, review, interpretation, negotiation and execution of all routine life sciences agreements, such as confidentiality, consulting, services, clinical trial, manufacturing, license and vendor agreements, while appropriately engaging the Executive Vice President and General Counsel for complicated terms or negotiations
  • Prepare materials for the Board and its Committees, including drafting minutes, policies, plan documents and additional materials, and helping to ensure compliance with applicable corporate governance requirements
  • Provide legal support for all aspects of financing and business development transactions
  • Provide legal support on employment matters, compensation, equity and benefit plans
  • Provide legal support in evaluating, advising on and handling corporate securities and SEC
    reporting and compliance matters, including SEC periodic reports, proxy statements and registration statements
  • Assist with a variety of other in-house legal matters, as requested by the Executive Vice President and General Counsel
  • Work with outside counsel and other advisors, as necessary
  • Interact with colleagues in the United States and United Kingdom on a daily basis, which will
    involve flexibility regarding time zones and working hours

Requirements:

  • Juris Doctorate (JD) degree from ABA accredited law school required
  • 7+ years of relevant corporate legal experience
  • In-house experience preferably at a pharma/biotech company
  • Experience at a law firm with a sophisticated general corporate, contracts, corporate
    governance and securities practice is preferred
  • Experience with SEC and NASDAQ compliance
  • Experience with life sciences patent and other intellectual property matters is a plus
  • Experience at companies with international operations a plus
  • Proven ability to identify emerging risks and trends, analyze and think strategically about
    complex risk issues and deliver solutions-oriented advice and solutions to mitigate or manage such risks

Skill and Knowledge:

  • Maintains the highest levels of ethics and integrity
  • Excellent written, oral, and presentation skills
  • Proven ability to work with all levels of management and the general workforce
  • Strong customer service and problem-solving skills
  • Demonstrated ability to partner effectively with others in addressing complex issues
  • Strong influencing skills and business judgment
  • Strong organizational and time management skills
  • Motivated, self-starter with ability to appropriately prioritize issues and allocate resources
  • Strategic, innovative and detail-oriented
  • Ability to work in an international organization across different time zones
  • Periodic travel in the United States and United Kingdom is required

Benefits

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Qualified candidates are encouraged to forward their resume to CareersUS@eliemtx.com

Accounts Payable Staff Accountant
Accounts Payable Staff Accountant

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases.  Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions.  The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering.  The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We are looking for an Accounts Payable Staff Accountant to join our growing global Accounting team. This new position is responsible for managing the global accounts payable function, including the timely processing, verification, tracking, reporting, and payment of all approved invoices.  Additionally, the Accounts Payable Staff Accountant will be recording journal entries into the company’s ERP system, performing account reconciliations, and assist in other accounting projects.  The Accounts Payable Staff Accountant must be self-motivated with an outstanding work ethic. The ideal candidate will have prior UK VAT experience, excellent communication and organizational skills, be able to work with cross-functional teams. As a results-oriented professional the Accounts Payable Staff Accountant will report directly to the Controller.

Responsibilities:

  • Full cycle global accounts payable (entering invoices, processing, paying invoices).  This includes USD and GBP invoices
  • Verify the accuracy of vendor invoices and employee expense reimbursements
  • Manage A/P inbox, responding timely to internal and external emails
  • Reconcile A/P accounts and vendor statements, including researching, conducting phone calls and correcting discrepancies
  • Maintain W-9 records and prepare annual 1099 reports
  • Coordinate monthly reconciliation of corporate credit cards
  • Assist with month-end close, including posting journal entries and preparing account reconciliations for accounts such as: cash, AP, expense accruals, prepaids, and fixed assets
  • Identify, track, and properly account for prepaid expenses
  • Assist with gathering documents to support auditors’ requests, when needed
  • Support the accounting team on special projects and other responsibilities as needed
  • Adhere to and maintain internal control processes surrounding vendor management and invoice processing
  • Assist with special projects, initiatives, and system/process improvements as needed
  • Ability to streamline processes and implement automation whenever possible

Experience/Skills:

  • Bachelor’s degree in Finance or Accounting (preferred)
  • Minimum 2 years of Accounts Payable experience
  • Experience processing foreign currency invoices required, with UK VAT experience highly preferred
  • Basic accounting knowledge and understanding of debits and credits
  • Strong organization and prioritization skills
  • Strong verbal and written communication, both with internal and external stakeholders
  • Ability to work independently and as part of a team, with emphasis on accuracy and timeliness
  • Ability to work successfully across international time zones, which may include working at non-standard business hours
  • Strong problem-solving skills, basic accounting principles knowledge, documentation skills, research and resolution skills, data analysis and multi-tasking skills
  • Proficiency in Microsoft Office products with advanced Excel skills

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options. Qualified candidates are encouraged to forward their resumes to CareersUS@eliemtx.com.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Senior Director, DMPK
Senior Director, DMPK

Location: Cambridge UK

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases.  Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions.  The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering.  The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We have a new opportunity for a Senior Director to head up the DMPK function across all our R&D projects, from early Discovery to Clinical Development. As a senior leader in DMPK science, reporting to the SVP & Chief Development Officer, you will be responsible for ensuring that world class science is applied to drive a translational understanding of drug disposition and PKPD in projects in a collaborative manner within R&D.

Key Responsibilities:

  • Lead the global DMPK function across multiple R&D projects, from early research stage projects through to approval
  • Drive best practice sharing across the team in support of global DMPK strategic direction
  • Develop and maintain excellent working relations within Eliem R&D to ensure strategic alignment and optimal cross-functional collaboration and communication
  • Ensure that translational PK/PD approaches and appropriate screening cascades with multiparametric optimization are being applied in Discovery projects
  • Responsible for coordinating and ensuring high-quality DMPK contributions to protocols, Investigator Brochure, regulatory submissions and internal project meetings
  • Ensure the use of ADME and PK modelling approaches in Development projects
  • Responsible for overseeing technical aspects of all outsourced DMPK work in vitro, in vivo and/or in silico methods and models to address absorption, distribution, metabolism, excretion (ADME) and bioanalysis
  • Efficiently manage demand and capacity of the DMPK CROs to ensure optimal support of all R&D projects
  • Develop and build a DMPK group, as required

Key Requirements:

  • PhD or equivalent in a field relevant to DMPK
  • Significant industry/CRO experience, built over many years
  • Experience managing projects, with demonstrated experience in strategy development
  • Experience engaging with external DMPK science community and key opinion leaders
  • In-depth experience of applying DMPK paradigms, including modelling approaches, to support Drug Discovery and Development projects
  • Knowledge of regulatory filing requirements and experience of regulatory interactions/communication
  • Ability to manage budgets and resources
  • Demonstrated ability to develop and maintain strong relationships and build partnerships with stakeholders
  • An enthusiastic leader with a proven track record to build and lead high-performing teams

We offer our employees competitive salary and benefits, including pension, life assurance, income protection, private medical insurance, bonus and share options.

To apply please send your CV and a covering letter to CareersUK@eliemtx.com, quoting job reference E21/05.

View all
Open Positions
Senior Director, DMPK
Accounts Payable Staff Accountant
Senior Corporate Counsel
Senior Manager – Technical Accounting and SEC Reporting
Senior Director, DMPK

Location: Cambridge UK

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases.  Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions.  The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering.  The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We have a new opportunity for a Senior Director to head up the DMPK function across all our R&D projects, from early Discovery to Clinical Development. As a senior leader in DMPK science, reporting to the SVP & Chief Development Officer, you will be responsible for ensuring that world class science is applied to drive a translational understanding of drug disposition and PKPD in projects in a collaborative manner within R&D.

Key Responsibilities:

  • Lead the global DMPK function across multiple R&D projects, from early research stage projects through to approval
  • Drive best practice sharing across the team in support of global DMPK strategic direction
  • Develop and maintain excellent working relations within Eliem R&D to ensure strategic alignment and optimal cross-functional collaboration and communication
  • Ensure that translational PK/PD approaches and appropriate screening cascades with multiparametric optimization are being applied in Discovery projects
  • Responsible for coordinating and ensuring high-quality DMPK contributions to protocols, Investigator Brochure, regulatory submissions and internal project meetings
  • Ensure the use of ADME and PK modelling approaches in Development projects
  • Responsible for overseeing technical aspects of all outsourced DMPK work in vitro, in vivo and/or in silico methods and models to address absorption, distribution, metabolism, excretion (ADME) and bioanalysis
  • Efficiently manage demand and capacity of the DMPK CROs to ensure optimal support of all R&D projects
  • Develop and build a DMPK group, as required

Key Requirements:

  • PhD or equivalent in a field relevant to DMPK
  • Significant industry/CRO experience, built over many years
  • Experience managing projects, with demonstrated experience in strategy development
  • Experience engaging with external DMPK science community and key opinion leaders
  • In-depth experience of applying DMPK paradigms, including modelling approaches, to support Drug Discovery and Development projects
  • Knowledge of regulatory filing requirements and experience of regulatory interactions/communication
  • Ability to manage budgets and resources
  • Demonstrated ability to develop and maintain strong relationships and build partnerships with stakeholders
  • An enthusiastic leader with a proven track record to build and lead high-performing teams

We offer our employees competitive salary and benefits, including pension, life assurance, income protection, private medical insurance, bonus and share options.

To apply please send your CV and a covering letter to CareersUK@eliemtx.com, quoting job reference E21/05.

< Back to listing
Accounts Payable Staff Accountant

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases.  Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions.  The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering.  The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We are looking for an Accounts Payable Staff Accountant to join our growing global Accounting team. This new position is responsible for managing the global accounts payable function, including the timely processing, verification, tracking, reporting, and payment of all approved invoices.  Additionally, the Accounts Payable Staff Accountant will be recording journal entries into the company’s ERP system, performing account reconciliations, and assist in other accounting projects.  The Accounts Payable Staff Accountant must be self-motivated with an outstanding work ethic. The ideal candidate will have prior UK VAT experience, excellent communication and organizational skills, be able to work with cross-functional teams. As a results-oriented professional the Accounts Payable Staff Accountant will report directly to the Controller.

Responsibilities:

  • Full cycle global accounts payable (entering invoices, processing, paying invoices).  This includes USD and GBP invoices
  • Verify the accuracy of vendor invoices and employee expense reimbursements
  • Manage A/P inbox, responding timely to internal and external emails
  • Reconcile A/P accounts and vendor statements, including researching, conducting phone calls and correcting discrepancies
  • Maintain W-9 records and prepare annual 1099 reports
  • Coordinate monthly reconciliation of corporate credit cards
  • Assist with month-end close, including posting journal entries and preparing account reconciliations for accounts such as: cash, AP, expense accruals, prepaids, and fixed assets
  • Identify, track, and properly account for prepaid expenses
  • Assist with gathering documents to support auditors’ requests, when needed
  • Support the accounting team on special projects and other responsibilities as needed
  • Adhere to and maintain internal control processes surrounding vendor management and invoice processing
  • Assist with special projects, initiatives, and system/process improvements as needed
  • Ability to streamline processes and implement automation whenever possible

Experience/Skills:

  • Bachelor’s degree in Finance or Accounting (preferred)
  • Minimum 2 years of Accounts Payable experience
  • Experience processing foreign currency invoices required, with UK VAT experience highly preferred
  • Basic accounting knowledge and understanding of debits and credits
  • Strong organization and prioritization skills
  • Strong verbal and written communication, both with internal and external stakeholders
  • Ability to work independently and as part of a team, with emphasis on accuracy and timeliness
  • Ability to work successfully across international time zones, which may include working at non-standard business hours
  • Strong problem-solving skills, basic accounting principles knowledge, documentation skills, research and resolution skills, data analysis and multi-tasking skills
  • Proficiency in Microsoft Office products with advanced Excel skills

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options. Qualified candidates are encouraged to forward their resumes to CareersUS@eliemtx.com.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

< Back to listing
Senior Corporate Counsel

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

The Senior Corporate Counsel is a newly created position at Eliem and will play a key role in the company’s legal department. Reporting directly to Eliem’s Executive Vice President and General Counsel, they will enjoy a varied role advising the company’s teams in the United States and United Kingdom. The Senior Corporate Counsel will work on a broad range of contracts, general corporate, compliance, governance, securities, human resources, benefits, and business development matters, and provide effective, business-focused legal advice and counsel to stakeholders across the organization. The level of counseling requires a deep understanding of life sciences businesses and related legal issues, as well as outstanding drafting and negotiation skills. The Senior Corporate Counsel may also provide support on various intellectual property matters as needed.

Responsibilities:

  • Lead the drafting, review, interpretation, negotiation and execution of all routine life sciences agreements, such as confidentiality, consulting, services, clinical trial, manufacturing, license and vendor agreements, while appropriately engaging the Executive Vice President and General Counsel for complicated terms or negotiations
  • Prepare materials for the Board and its Committees, including drafting minutes, policies, plan documents and additional materials, and helping to ensure compliance with applicable corporate governance requirements
  • Provide legal support for all aspects of financing and business development transactions
  • Provide legal support on employment matters, compensation, equity and benefit plans
  • Provide legal support in evaluating, advising on and handling corporate securities and SEC
    reporting and compliance matters, including SEC periodic reports, proxy statements and registration statements
  • Assist with a variety of other in-house legal matters, as requested by the Executive Vice President and General Counsel
  • Work with outside counsel and other advisors, as necessary
  • Interact with colleagues in the United States and United Kingdom on a daily basis, which will
    involve flexibility regarding time zones and working hours

Requirements:

  • Juris Doctorate (JD) degree from ABA accredited law school required
  • 7+ years of relevant corporate legal experience
  • In-house experience preferably at a pharma/biotech company
  • Experience at a law firm with a sophisticated general corporate, contracts, corporate
    governance and securities practice is preferred
  • Experience with SEC and NASDAQ compliance
  • Experience with life sciences patent and other intellectual property matters is a plus
  • Experience at companies with international operations a plus
  • Proven ability to identify emerging risks and trends, analyze and think strategically about
    complex risk issues and deliver solutions-oriented advice and solutions to mitigate or manage such risks

Skill and Knowledge:

  • Maintains the highest levels of ethics and integrity
  • Excellent written, oral, and presentation skills
  • Proven ability to work with all levels of management and the general workforce
  • Strong customer service and problem-solving skills
  • Demonstrated ability to partner effectively with others in addressing complex issues
  • Strong influencing skills and business judgment
  • Strong organizational and time management skills
  • Motivated, self-starter with ability to appropriately prioritize issues and allocate resources
  • Strategic, innovative and detail-oriented
  • Ability to work in an international organization across different time zones
  • Periodic travel in the United States and United Kingdom is required

Benefits

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Qualified candidates are encouraged to forward their resume to CareersUS@eliemtx.com

< Back to listing
Senior Manager – Technical Accounting and SEC Reporting

Location: Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and recently completed its initial public offering. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com

About this role:

We are looking for a Senior Manager – Technical Accounting and SEC Reporting to join our growing global Accounting team. This is a crucial role that will assist in overseeing financial reporting in our transition to a public company. This role will report to the VP of Accounting and work with key internal and external stakeholders to deliver timely internal and external reporting in accordance with GAAP.

Responsibilities:

  • Manage SEC filings and supporting documents, including Form 10-K, 10-Q, proxy statements, and other required form filings
  • Independently research and analyze accounting issues and disclosure requirements in accordance with US GAAP and SEC reporting requirements
  • Preparing cash flows, stockholders’ rollforward, EPS calculation, stock-based compensation, and accounting for non-routine transactions
  • Complete disclosure checklists to ensure all disclosure requirements are met; research disclosure requirements and keep abreast of new pronouncements impacting disclosures; establish a repository of internal practices and peer company disclosures
  • Monitor proposed and enacted accounting pronouncements that affect the Company and make recommendations on implementing changes/compliance
  • Collaborate with finance, investor relations and legal on external stakeholder financial communications
  • Review XBRL tagging in connection with Form 10-K and 10-Q filings
  • Ensure compliance with Sarbanes-Oxley (SOX) controls as it pertains to financial reporting and
    equity processes
  • Assist with the implementation of accounting and other systems for better financial and operational reporting and an improved control environment
  • Assist in various ongoing and ad-hoc projects or initiatives as needed

Experience:

  • Bachelor’s degree in Accounting/Finance and CPA required
  • Strong, current understanding of US GAAP and SEC reporting rules and regulations
  • 6+ years of experience in accounting; including Big 4 public accounting experience and
    experience with financial reporting in a public company
  • Strong project management skills and the ability to manage a process and team to multi-task,
    work under pressure, and meet deadlines in a fast-paced work environment
  • Active Disclosure and XBRL experience preferred
  • Strong organizational, verbal, and written communication skills are a must
  • Accounting research and problem-solving skills required
  • Ability to build strong relationships with internal and external business partners
  • Ability to operate independently and as part of a larger functional team
  • Proficient with Microsoft Office – Word, Excel, and PowerPoint
  • Experience with NetSuite is a plus

Benefits

We offer our employees competitive compensation and benefits, including paid time off, health insurance, life and disability insurance, a 401(k) plan, and stock options.

Eliem is an Equal Opportunity Employer and we do not discriminate against any employee or applicant for employment because of race, color, sex, age, place of origin, religion, family status, sexual orientation, gender identity, status as a veteran, and disability or any other federal, state, provincial or local protected ground.

Qualified candidates are encouraged to forward their resume to CareersUS@eliemtx.com

< Back to listing

Contact Us

MEDIA
INVESTOR RELATIONS
HUMAN RESOURCES
PARTNERING
Eliem Therapeutics, Inc.
23515 NE Novelty Hill Road, Suite B221 #125
Redmond, WA 98053

Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT